gemfibrozil has been researched along with Graves Disease in 1 studies
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, A | 1 |
| Ferrari, SM | 1 |
| Frascerra, S | 1 |
| Pupilli, C | 1 |
| Mancusi, C | 1 |
| Metelli, MR | 1 |
| Orlando, C | 1 |
| Ferrannini, E | 1 |
| Fallahi, P | 1 |
1 other study available for gemfibrozil and Graves Disease
| Article | Year |
|---|---|
CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
Topics: Adult; Chemokine CXCL11; Chemokine CXCL9; Cytokines; Female; Fenofibrate; Gemfibrozil; Graves Diseas | 2010 |